3Gerbes AL, Bertheau -Reitha U, Falkner C, et al. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross - over trial[J]. J Hepatol, 1993, 17(3) : 353 -358.
4European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontane- ous bacterial peritonitis, and hepatorenal syndrome in cirrho- sis[J]. J Hepatol, 2010, 53(3) .. 397 -417.
5Runyon BA. Management of adult patients with ascites due to cirrhosis : an update[ J ]. Hepatology, 2009, 49 (6) : 2087 -2107.
6Cardenas A, Gines P, Marotta P, et al. Tolvaptan, an oral vaso-pressin antagonist, in the treatment of hyponatremia in cirrhosis[J]. J Hepatol, 2012, 56(3); 571 -578.
7Krag A, Bendtsen F, Pedersen EB, et al. Effects of terlip- ressin on the aquaretic system evidence of antidiuretic effects[J]. Am J Physiol Renal Physiol, 2008, 295(5); 1295 - 1300.
8Xing F, Tan Y, Yan G J, et al. Effects of Chinese herbal cata- plasm Xiaozhang Tie on cirrhotic ascites[ J ]. J Ethnopharma- co, 2012, 139(2) : 343 -349.
